Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure

Documenti analoghi

• Association of Gadolinium Based MRI Contrast Agents and Nephrogenic Systemic Fibrosis
  di: Bhave, Gautam, et al.
  Pubblicazione: (2008)
• Biochemical Safety Profiles of Gadolinium-Based Extracellular Contrast Agents and Nephrogenic Systemic Fibrosis
  di: Ersoy, Hale, et al.
  Pubblicazione: (2007)
• Gadolinium Contrast Agent-Induced CD163(+) Ferroportin(+) Osteogenic Cells in Nephrogenic Systemic Fibrosis
  di: Swaminathan, Sundararaman, et al.
  Pubblicazione: (2013)
• An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis
  di: Zhang, Bin, et al.
  Pubblicazione: (2015)
• Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
  di: Thomsen, Henrik S., et al.
  Pubblicazione: (2007)